• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Who We Are

The International Alliance of ALS/MND Associations was founded in 1992. Today, we bring together almost 80 member organizations across the globe, united by a single purpose: driving global collaboration toward a world free of ALS/MND.

Everything we do is centred around the fundamental rights of people affected by ALS/MND — the belief that where you live should not determine the quality of care, support, and respect you receive.

We work alongside our members to raise awareness, coordinate research, advocate for equitable access to care and therapies, and ensure that under-represented communities are not left behind. Our global reach means that knowledge, tools, and best practices developed anywhere in the world can benefit people everywhere.

Our Vision: A world free of ALS/MND

Our Aspiration: To drive global collaboration

Our Reach: We work globally, serving the entire ALS/MND community — people living with the disease, caregivers, clinicians, researchers, and the organizations that support them.

Our Purpose: Everything we do is oriented around one purpose: accelerating progress on the Fundamental Rights of people affected by ALS/MND, everywhere in the world.

Our Strategic Priorities

The Alliance’s 2026–2028 Strategy sets out six priorities that will guide our work over the coming years.

  • Bring focus to quality of life for PALS and their community: We advocate more effectively to improve outcomes by understanding what people living with ALS/MND (PALS) and their community identify as important.
  • Include under-represented communities: By working alongside under-represented communities, we ensure meaningful inclusion across the globe so geography does not dictate destiny.
  • Increase awareness of ALS/MND: By raising awareness of ALS/MND and the Alliance, we strengthen our advocacy efforts at the global level, which supports our members at the local level.
  • Facilitate research coordination: By bringing people together and facilitating research coordination across the globe, we deepen our understanding of ALS/MND and accelerate research.
  • Leverage collective capacity: By coordinating with our members and partnering in strategic international collaborations, we leverage collective knowledge and resources — positioning the Alliance as a trusted source of evidence-based information, best practices, and tools.
  • Grow the community: By identifying and inviting ALS/MND organizations not yet part of the Alliance, and by supporting the creation and development of new organizations, we expand the community working toward a world free of ALS/MND.

Alliance Strategy 2026-2028: Our three-year roadmap for driving global collaboration toward a world free of ALS/MND.

Annual Report 2024-2025: A review of the Alliance’s work and impact over the past year.

Primary Sidebar

About

  • Who We Are
  • Board of Trustees
  • Councils, Forums & Committees
    • PALS and CALS Advisory Council
    • Scientific Advisory Council
    • Advocacy and Public Policy Forum
    • Research Directors Forum
    • Governance Committee
    • Finance Committee
  • Staff
  • History
  • Newsletter Archive
    • Newsletters
    • Meetings
  • Awards

  • Mauril Belanger, Canada

    Mauril Belanger, Canada

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Josée Kolijn-de Man, Netherlands

    Josée Kolijn-de Man, Netherlands

  • Liam Dwyer, England

    Liam Dwyer, England

  • Feng Gin Sun, China

    Feng Gin Sun, China

  • Ailsa Malcolm-Hutton, UK

    Ailsa Malcolm-Hutton, UK

  • Mark Miller, UK

    Mark Miller, UK

  • Enzo Maccarrone, Italy

    Enzo Maccarrone, Italy

  • PALS and CALS, Singapore

    PALS and CALS, Singapore

  • Brigitte Wernli, Switzerland

    Brigitte Wernli, Switzerland

  • Murat Morali, Turkey

    Murat Morali, Turkey

  • Irene McCaughey, Australia

    Irene McCaughey, Australia

  • Lee Millard, England

    Lee Millard, England

  • Lombana, Spain

    Lombana, Spain

  • Kris Van Reusel, Belgium

    Kris Van Reusel, Belgium

  • Brian Parsons, Canada

    Brian Parsons, Canada

  • Erwin Coppejans, Belgium

    Erwin Coppejans, Belgium

  • Elkin Ramiro Gaviria Muñoz, Colombia

    Elkin Ramiro Gaviria Muñoz, Colombia

  • Shaleen Latchman, Canada

    Shaleen Latchman, Canada

  • Ali Var, Turkey

    Ali Var, Turkey

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Wiebke Braach, Germany

    Wiebke Braach, Germany

  • Patrick Shuma, Kenya

    Patrick Shuma, Kenya

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • David Watson, Scotland

    David Watson, Scotland

  • Teddy Hanono Annie, Mexico

    Teddy Hanono Annie, Mexico

  • Cath Muir, UK

    Cath Muir, UK
    Cath

  • Federica Mastrosimone, Italy

    Federica Mastrosimone, Italy

  • Mike Small, UK

    Mike Small, UK

  • Semra Gokalp, Turkey

    Semra Gokalp, Turkey

  • Jack Buzby, USA

    Jack Buzby, USA

  • Rosie Riley, USA

    Rosie Riley, USA

  • Carlos Gomez Matallanas, Spain

    Carlos Gomez Matallanas, Spain

  • Osiel Mendoza, USA

    Osiel Mendoza, USA

  • Chun Ju Xiao, China

    Chun Ju Xiao, China

  • Emilienne Verhaegen, Belgium

    Emilienne Verhaegen, Belgium

  • John Russo, USA

    John Russo, USA
    final3878

  • Nicholas (Nic) Bowman, South Africa

    Nicholas (Nic) Bowman, South Africa

  • Horacio Fritzer, Argentina

    Horacio Fritzer, Argentina

  • Wilfried Leusing, Germany

    Wilfried Leusing, Germany

  • Chen Yin Xue, Taiwan

    Chen Yin Xue, Taiwan

  • Art Eggert, USA

    Art Eggert, USA

  • Jeff Sutherland, Canada

    Jeff Sutherland, Canada
    jspic

  • Lucy Lintott, Scotland

    Lucy Lintott, Scotland

  • Frank Taylor, USA

    Frank Taylor, USA

  • Yannick Richard, Canada

    Yannick Richard, Canada
    yannickrichard

  • Margarita Pizarro, Argentina

    Margarita Pizarro, Argentina

  • Brian Lovell, Australia

    Brian Lovell, Australia

  • Duncan Bayly, Australia

    Duncan Bayly, Australia

  • Karl Hughes, Ireland

    Karl Hughes, Ireland

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login